Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has earned a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $54.50.

A number of analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Bank of America upgraded shares of Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Wednesday, February 4th. Benchmark lifted their target price on shares of Omnicell from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Piper Sandler reaffirmed an “overweight” rating and issued a $49.00 price target (down from $63.00) on shares of Omnicell in a research note on Friday, February 6th. Finally, KeyCorp upgraded Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a report on Wednesday, January 7th.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of Omnicell stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the sale, the executive vice president directly owned 91,674 shares in the company, valued at $4,574,532.60. The trade was a 6.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.52% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. WINTON GROUP Ltd acquired a new stake in shares of Omnicell in the 2nd quarter valued at $2,692,000. Advantage Alpha Capital Partners LP bought a new position in Omnicell during the second quarter valued at about $2,476,000. Assenagon Asset Management S.A. lifted its position in shares of Omnicell by 1,316.2% in the third quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock worth $4,284,000 after buying an additional 130,742 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Omnicell by 33.9% during the 2nd quarter. Acadian Asset Management LLC now owns 168,519 shares of the company’s stock worth $4,946,000 after acquiring an additional 42,676 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Omnicell during the 2nd quarter valued at about $282,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $41.93 on Friday. The company’s fifty day moving average is $45.16 and its two-hundred day moving average is $37.85. The company has a market cap of $1.88 billion, a P/E ratio of 1,048.51, a price-to-earnings-growth ratio of 1.45 and a beta of 0.78. Omnicell has a 12-month low of $22.66 and a 12-month high of $55.00. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The business had revenue of $313.98 million for the quarter, compared to analysts’ expectations of $313.36 million. Omnicell had a net margin of 0.17% and a return on equity of 3.00%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 EPS. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Equities analysts expect that Omnicell will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.